Vaccine Studies in HIV-infected Subjects

HIV 感染者的疫苗研究

• 批准号: 8148436
• 负责人: Barney Graham
• 金额: $ 55.53万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8148436
• 关键词: DNA; Educational Materials; Eligibility Determination; Enrollment; Goals; HIV-1; Immune response; Individual; Infection; Medication Management; Phase; Recruitment Activity; Screening Result; Therapeutic; Therapeutic Studies; Vaccines

VRC 100 was designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study were used to determine if the subject met eligibility requirements for participation a vaccine study. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into a vaccine study. VRC 101 was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.

VRC 100旨在招募和筛查艾滋病毒感染的受试者，以用于治疗性HIV疫苗，以及用于在HIV感染者中使用的其他疫苗。该筛查研究的结果用于确定受试者是否满足参与的资格要求。对疫苗的教育材料进行了审查并提供给受试者，然后才入学疫苗研究。 VRC 101是VRC开发的两种候选HIV-1疫苗的第一阶段治疗研究，并在Prime-bumost方案中施用。